HK40029614A - Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma - Google Patents

Description

Use of 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine for the treatment of diffuse large B-cell lymphoma

The present invention relates to the use of 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A), more particularly (+) 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A'), for the treatment of diffuse large B-cell lymphoma (DLBCL), in particular in diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular in cells thereof having an amplification or translocation of the MYC gene and/or the BCL2 gene, and/or MYC and/or BCL2 in an overexpressed diffuse large B-cell lymphoma.

The family of cyclin-dependent kinase (CDK) proteins consists of members that are key regulators of the cell division cycle (cell cycle CDKs), members involved in the regulation of gene transcription (transcriptional CDKs) and members with other functions. CDKs require activation and regulation of cyclin subunit binding. The cell cycle CDKs CDK 1/cyclin B, CDK 2/cyclin A, CDK 2/cyclin E, CDK 4/cyclin D and CDK 6/cyclin D are sequentially activated to drive the cell into and through the cell division cycle. Transcription CDKs CDK 9/cyclin T and CDK 7/cyclin H regulate the activity of RNA polymerase II through phosphorylation of the carboxy-terminal domain (CTD). Positive transcription factor b (P-TEFb) is a heterodimer of CDK9 and is one of four cyclin chaperones (cyclin T1, cyclin K, cyclin T2a or T2 b).

CDK9(NCBI GenBank gene ID 1025) is exclusively involved in transcriptional regulation, while CDK7 is additionally involved in cell cycle regulation as a CDK-activated kinase (CAK).

Gene transcription by RNA polymerase II is initiated by assembling a pre-initiation complex in the promoter region and phosphorylating Ser 5 and Ser 7 of CTD by CDK 7/cyclin H. For most genes, RNA polymerase II stops mRNA transcription after the mRNA has moved 20-40 nucleotides along the DNA template. This proximal pausing of the promoter of RNA polymerase II is mediated by negative elongation factors and is considered to be the main regulatory mechanism for regulating rapidly induced gene expression in response to a variety of stimuli (Cho et al, Cell Cycle 2010,9, 1697). P-TEFb is critically involved in overcoming the promoter proximal pause of RNA polymerase II and in the transition to the productive elongation state by phosphorylation of Ser 2 of CTD and by phosphorylation and inactivation of negative elongation factors.

The activity of P-TEFb itself is regulated by a variety of mechanisms. Approximately half of the cells P-TEFb are present in an inactivated complex with 7SK micronucleus RNA (7SK snRNA), La-associated protein 7(LARP7/PIP7S), and hexamethylene bisacetamide-inducing protein 1/2 (HEXIM1/2, He et al, mol. cell 2008,29, 588). The remaining half of the P-TEFb is present in the active complex containing the bromodomain protein Brd4 (Yang et al, mol. cell 2005,19, 535). Brd4 is prepared for gene transcription by interacting with acetylated histones to recruit P-TEFb to the chromatin region. By alternating interaction with its positive and negative regulators, P-TEFb maintains a functional balance: the P-TEFb bound to the 7SK snRNA complex acts as a reservoir from which active P-TEFb can be released according to the needs of cell transcription and cell proliferation (Zhou & Yik, microbiol. mol. biol. rev.2006,70,646). Furthermore, the activity of P-TEFb is regulated by post-translational modifications, including phosphorylation/dephosphorylation, ubiquitination and acetylation (for review, Cho et al, Cell Cycle 2010,9, 1697).

Dysregulated CDK9 kinase activity of P-TEFb heterodimers is associated with a variety of human pathological conditions, such as hyperproliferative diseases (e.g., cancer), virally-induced infectious diseases, or cardiovascular diseases.

Cancer is considered to be a hyperproliferative disorder mediated by an imbalance of proliferation and cell death (apoptosis). Anti-apoptotic Bcl-2 family proteins are found at high levels in a variety of human tumors and can prolong tumor cell survival and therapeutic tolerance. Inhibition of P-TEFb kinase activity has been shown to decrease the transcriptional activity of RNA polymerase II, leading to a decrease in short-lived anti-apoptotic proteins (especially Mcl-1 and XIAP), thereby reestablishing the ability of tumor cells to undergo apoptosis. Many other proteins associated with transformed tumor phenotypes (e.g., Myc, NF-kB responsive gene transcripts, mitotic kinases) are or are encoded by short-lived proteins that are sensitive to a decrease in RNA polymerase II activity mediated by P-TEFb inhibition (reviewed in Wang & Fischer, Trends pharmacol. sci.2008,29,302).

Many viruses rely on the transcriptional machinery of the host cell to carry out transcription of their own genome. For HIV-1, RNA polymerase II is recruited to the promoter region in the viral LTR. The viral transcription activator (Tat) protein binds to nascent viral transcripts and overcomes promoter proximal RNA polymerase II pause by recruiting P-TEFb, which in turn promotes transcriptional elongation. Furthermore, Tat protein increases the proportion of active P-TEFb by replacing the P-TEFb inhibitory protein HEXIM1/2 in the 7SK snRNA complex. Recent data show that inhibition of the kinase activity of P-TEFb is sufficient to prevent HIV-1 replication at kinase inhibitor concentrations that are not cytotoxic to the host cell (for review, Wang & Fischer, Trends pharmacol. sci.2008,29,302). Similarly, it has been reported that for other viruses, such as Epstein-Barr virus associated with B-cell cancer (Bark-Jones et al, Oncogene 2006,25,1775) in which the nuclear antigen EBNA2 protein interacts with P-TEFb, and human T-cell tropic virus type 1 (HTLV-1) in which the transcriptional activator Tax recruits P-TEFb (Zhou et al, j.virol.2006,80,4781), P-TEFb is recruited by viral proteins.

Cardiac hypertrophy is the adaptive response of the heart to mechanical load and stress (hemodynamic stress, e.g. hypertension, myocardial infarction) and in the long term leads to heart failure and death. Cardiac hypertrophy has been shown to be associated with increased transcriptional activity and RNA polymerase II CTD phosphorylation in cardiomyocytes. P-TEFb was found to be activated by dissociation from the inactive 7SK snRNA/HEXIM1/2 complex. These findings indicate that pharmacological inhibition of P-TEFb kinase activity is a therapeutic approach to the treatment of cardiac hypertrophy (reviewed in Dey et al, Cell Cycle 2007,6, 1856).

In summary, there is a number of lines of evidence that selective inhibition of CDK9 kinase activity of P-TEFb heterodimers (═ CDK9 and one of the four cyclin chaperones, cyclin T1, cyclin K, cyclin T2a or T2b) represents an innovative approach to the treatment of diseases such as cancer, viral diseases and/or cardiac diseases. CDK9 belongs to at least 13 closely related kinase families, a subset of whose cell cycle CDKs play multiple roles in regulating cell proliferation. Thus, co-inhibition of cell cycle CDKs (e.g., CDK 1/cyclin B, CDK 2/cyclin A, CDK 2/cyclin E, CDK 4/cyclin D, CDK 6/cyclin D) and CDK9 is expected to affect normal proliferative tissues, such as intestinal mucosa, lymphoid and hematopoietic organs, as well as reproductive organs. To maximize the therapeutic margin of CDK9 kinase inhibitors, molecules with high selectivity for CDK9 are therefore needed.

In general, CDK inhibitors as well as CDK9 inhibitors are described in a number of different publications:

WO2008129070 and WO2008129071 generally describe 2, 4-disubstituted aminopyrimidines as CDK inhibitors. It is also believed that some of these compounds may act as selective CDK9 inhibitors (WO2008129070) and CDK5 inhibitors (WO2008129071), respectively, but specific CDK9 IC50(WO2008129070) or CDK5 IC50(WO200812971) data are not shown.

WO2008129080 discloses 4, 6-disubstituted aminopyrimidines and demonstrates that these compounds have an inhibitory effect on the protein kinase activity of various protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6 and CDK9, preferably CDK9 (example 80).

EP1218360B1 describes triazine derivatives as kinase inhibitors, but no potent or selective CDK9 inhibitors are disclosed.

WO2008079933 discloses aminopyridine and aminopyrimidine derivatives and their use as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 or CDK9 inhibitors.

WO2011012661 describes aminopyridine derivatives useful as CDK inhibitors.

Wang et al (Chemistry & Biology 2010,17,1111-1121) describe 2-anilino-4- (thiazol-5-yl) pyrimidine transcriptional CDK inhibitors which show anticancer activity in animal models.

WO2004009562 discloses substituted triazine kinase inhibitors. CDK1 and CDK4 test data, but no CDK9 data, were shown for selected compounds.

WO2004072063 describes heteroaryl (pyrimidine, triazine) substituted pyrroles as inhibitors of protein kinases such as ERK2, GSK3, PKA or CDK 2.

WO2010009155 discloses triazine and pyrimidine derivatives as inhibitors of histone deacetylase and/or Cyclin Dependent Kinases (CDKs). CDK2 test data was described for selected compounds.

WO2003037346 (corresponding to US7618968B2, US7291616B2, US2008064700a1, US2003153570a1) relates to aryl triazines and uses thereof, including inhibition of lysophosphatidic acid acyltransferase β (LPAAT- β) activity and/or proliferation of cells, such as tumor cells.

WO2008025556 describes carbamoyl sulfinimides having a pyrimidine core, which are useful as kinase inhibitors. CDK9 data is not shown.

WO2002066481 describes pyrimidine derivatives, does not mention the cyclin-dependent kinase inhibitor CDK9, and does not show CDK9 data.

WO2008109943 relates to phenyl aminopyridine (pyrimidine) compounds and their use as kinase inhibitors, in particular as JAK2 kinase inhibitors. Specific examples focus on compounds having a pyrimidine core.

WO2009032861 describes substituted pyrimidinamines as JNK kinase inhibitors. Specific examples focus on compounds having a pyrimidine core.

WO2011046970 relates to aminopyrimidine compounds as TBKL and/or IKK inhibitors. Specific examples focus on compounds having a pyrimidine core.

WO2012160034 describes compounds of the present invention. Disclosed are compounds that inhibit cell proliferation of HeLa cells (cervical cancer), HeLa/MaTu/ADR cells (cervical cancer), NCI-H460 cells (non-small cell lung cancer), DU145 cells (hormone-independent human prostate cancer), Caco-2 cells (colorectal cancer), and B16F10 cells (melanoma).

It is an object of the present invention to improve the treatment of diffuse large B-cell lymphoma (DLBCL).

Treatment of diffuse large B-cell lymphoma

Malignancies of B and T lymphocytes can be broadly described as hodgkin's lymphoma and non-hodgkin's lymphoma. Furthermore, non-hodgkin's lymphoma represents a large variety of diseases, each of which has unique epidemiological, etiological, morphological, immunophenotypic and clinical characteristics. The World Health Organization (WHO) reclassified non-Hodgkin's lymphomas in 2008 and now better reflected our understanding of the disease entities and their relationship to the immune system (JaffeES. the 2008WHO classification of lymphoma: injections for clinical practice and metabolic research. the health Am Soc liver animal Program 2009: 523-.

DLBCL is an aggressive disease and is the most common subtype of non-hodgkin lymphoma, accounting for up to 30-40% of newly diagnosed cases in western countries (Roman E, Smith ag. epidemiology of lymphoma. histopathlogy.2011; 58: 4-14). The primary therapy for advanced DLBCL is combined chemoimmunotherapy, in particular R-CHOP (rituximab), cyclophosphamide (cyclophosphaspamide), doxorubicin (doxorubicin), vincristine (vincristine), and prednisone). The introduction of rituximab into this chemotherapy regimen is the basis for a sustained and meaningful improvement of the prognosis of DLBCL patients. However, approximately 30% to 40% of patients develop recurrent or refractory disease after R-CHOP treatment that does not respond well to R-CHOP treatment, or relapse (Camcia R et al. Novel drug targets for systemic therapy mediated/recurrent drug large B-cell lymphoma: a comprehensive review. MolCancer. 2015; 14: 207). As a result, a variety of therapeutic approaches have been explored in an attempt to improve prognosis, including providing more chemotherapy courses, dose-intensive and alternative drug combinations, and high-dose chemotherapy followed by autologous stem cell transplantation. However, there is little evidence that these therapies have better efficacy than R-CHOP.

Gene Expression Profiling (GEP) studies have identified two distinct molecular subtypes, termed germinal center B cell (GCB) -DLBCL and Activated B Cell (ABC) -DLBCL, accounting for up to 45% and 35% of DLBCL-NOS cases, respectively (Martelli M, Ferreri AJ, Agostinell C, Di Rocco A, Pfunundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev on col Hematol.2013; 87: 146-71). Various studies have correlated MYC translocation with poorer prognosis in DLBCL patients receiving R-CHOP treatment, but newer studies have shown that secondary hit (double-hit) translocation concurrent with BCL2 results in a refractory patient group with lower median survival. This type of secondary hit translocation is more common in GCB-DLBCL and accounts for about 5% of all cases, while dual overexpression of both proteins is even more common (25% of DLBCL cases) and is more common in ABC-DLBCL and results in a significantly poorer prognosis compared to patients expressing only one protein or neither protein (Johnson NA, Slack GW, SavageKJ et al, Current expression of MYC and BCL2 in poor muscle B-cell methylated with rituximab plus cyclophamide, doxorubicin, vincristine, andprednisone. J Clin Oncol.2012; 30: 3452-.

Therapeutic targeting of specific molecular pathways involved in the development of DLBCL ultimately may improve patient prognosis. Several novel drugs are being evaluated, either as single drugs in recurrent disease conditions or in combination with R-CHOP, including immunomodulatory drugs (IMiD), protein kinase C inhibitors, histone deacetylase inhibitors, proteasome inhibitors and mTOR (mammalian target of rapamycin) inhibitors, BTK inhibitors, SYK inhibitors, PKC β inhibitors, PI3K inhibitors, and BCL2 inhibitors (Sehn LH, Gascoyne RD. Diffumose Large B-Cell Lymphoma: optimizing the injection of drugs in the clinical context of clinical and biochemical analysis, blood. 488; 125: 22-32; Boyle J et al, stimulating com in Advance DLBCL: systematic inactions and therapy, science in science (Willison Park) (2014; 28: 16: history 202929; human therapy J et al; wild therapy approach 202929: Cell J et al).

Therefore, there is a need for alternative therapies against DLBCL, in particular against recurrent or aggressive disease subpopulations.

It has now been found that the compound 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A, formula (I)),

more particularly, it is preferred that the first and second,

(+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A'),

plays a role in specific tumor types not previously considered, namely in diffuse large B-cell lymphoma (DLBCL), especially in diffuse large B-cell lymphoma of germinal center B-cell type, and especially in diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A) is a selected sulfinimide-substituted anilinopyrimidine derivative that can be separated into two stereoisomers, namely:

(+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A'), and

(-) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A ").

Compound a 'is preferred and is used in clinical development as compound a'.

In the case of compound a mentioned below, both pure stereoisomers a' and a "are meant, as well as any mixture of the two.

The present invention relates to 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A) or one of its physiologically acceptable salts or enantiomers, more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts, for use in the treatment and/or prevention of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular the use of diffuse large B-cell lymphomas whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

The invention also relates to 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A) or one of its physiologically acceptable salts or enantiomers, more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts, for the preparation of a medicament for the treatment of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal central B-cell type, and in particular the use of a medicament whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an over-expressed diffuse large B-cell lymphoma of MYC and/or BCL 2.

Another aspect of the invention is 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of the formula (I) (Compound A) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts,

use in the manufacture of a medicament for the treatment of cancer in a subject, wherein the medicament is prepared for the treatment of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

The invention also provides 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of the formula I (Compound A) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts,

it is used for the treatment of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the central B-cell type, and especially diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

The invention also relates to 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of the formula I (Compound A) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts,

for use in a method of treatment and/or prevention of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

Another aspect of the invention is a method for the treatment and/or prevention of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL2, using an effective amount of 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of formula I (compound a) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A') or one of its physiologically acceptable salts.

The present invention further provides a pharmaceutical composition comprising 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a) or one of its physiologically acceptable salts or enantiomers, more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a') or one of its physiologically acceptable salts, for use in the treatment of diffuse large B-cell lymphoma (DLBCL).

The invention also relates to a pharmaceutical composition comprising 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of formula I (Compound A) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a') or one of its physiologically acceptable salts and at least one inert, non-toxic, pharmaceutically suitable adjuvant are used for the treatment and/or prevention of diffuse large B-cell lymphoma (DLBCL).

The invention further provides a combination of 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a) or one of its physiologically acceptable salts or enantiomers, more particularly of (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a') or one of its physiologically acceptable salts with at least one further active ingredient for the treatment of diffuse large B-cell lymphoma (DLBCL), especially diffuse large B-cell lymphoma of the germinal center B-cell type, and especially diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

The invention also relates to a pharmaceutical composition comprising 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of formula I (Compound A) or one of its physiologically acceptable salts or enantiomers,

more particularly, (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (compound a') or one of its physiologically acceptable salts and at least one or more other active ingredients, for use in the treatment and/or prevention of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and in particular diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or the BCL2 gene and/or an overexpression of MYC and/or BCL 2.

The use of physiologically tolerable salts of compound a is likewise to be considered as encompassed by the present invention.

Physiologically safe salts of compound a include acid addition salts of inorganic acids, carboxylic and sulfonic acids, for example, salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic, acetic, trifluoroacetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic and benzoic acids.

Physiologically safe salts of compound a also include salts with common bases, such as, by way of example and preferably, alkali metal salts (e.g. sodium and potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts), and ammonium salts derived from ammonia or organic amines having 1 to 16C atoms (e.g. by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine).

The invention also provides a medicament comprising compound a and at least one or more other active ingredients for use in the treatment of diffuse large B-cell lymphoma (DLBCL), in particular diffuse large B-cell lymphoma of the germinal center B-cell type, and especially diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

Compound a may have systemic and/or local activity. For this purpose, it can be administered in a suitable manner, for example, orally, parenterally, by the pulmonary route, nasally, sublingually, lingually, buccally, rectally, vaginally, dermally, transdermally, conjunctivally, ocularly (otically), or as an implant or stent.

For these routes of administration, the compounds A according to the invention can be administered in a suitable administration form.

Oral administration forms suitable for delivering the compounds a of the invention in a crystalline and/or amorphous and/or dissolved form, which function according to the prior art and which comprise the compounds a of the invention, in a modified manner, are, for example, tablets (uncoated or coated tablets, for example with coatings resistant to gastric juices or delayed dissolution or insolubilization and controlled release of the compounds of the invention), tablets which disintegrate rapidly in the oral cavity, or films/flakes (wafers), films/lyophilisates, capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pills, powders, emulsions, suspensions, aerosols or solutions.

Parenteral administration can be carried out avoiding absorption steps (e.g., intravenous, intra-arterial, intracardiac, intraspinal or intralumbar) or involving absorption (e.g., intramuscular, subcutaneous, intradermal, transdermal or intraperitoneal). Administration forms suitable for parenteral administration are, in particular, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.

Examples of suitable for other routes of administration are pharmaceutical forms for inhalation [ especially powder inhalers, nebulizers ], nasal drops, nasal solutions, nasal sprays; tablets, films/sheets or capsules for lingual, sublingual or buccal administration; suppositories; formulations for the eyes and ears, eye washes, eye inserts, ear drops, ear powders, ear washes, ear plugs; vaginal capsules, aqueous suspensions (lotions, shaking mixtures (mixturae)), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g., patches), milks, pastes, foams, dusting powders, implants or stents.

Compound a can be converted into the administration form. This can be carried out in a manner known per se by mixing with inert, non-toxic, pharmaceutically suitable adjuvants. These adjuvants include, inter alia:

fillers and excipients (e.g. cellulose, microcrystalline cellulose (e.g. cellulose)) Lactose, mannitol, starch, calcium phosphate (e.g. calcium phosphate)))，

Ointment bases (e.g. petrolatum, paraffin, triglycerides, waxes, wool wax, lanolin alcohols, lanolin, hydrophilic ointments, polyethylene glycols),

bases for suppositories (e.g. polyethylene glycol, cocoa butter, solid fats)

Solvents (e.g. water, ethanol, isopropanol, glycerol, propylene glycol, medium chain triglyceride fatty oils, liquid polyethylene glycols, paraffin waxes),

surfactants, emulsifiers, dispersants or wetting agents (e.g. sodium lauryl sulfate, lecithin, phospholipids, fatty alcohols (e.g.,) Sorbitan fatty acid esters (e.g., sorbitan fatty acid esters)) Polyoxyethylene sorbitan fatty acid esters (for example,) Polyoxyethylene fatty acid glycerides (for example,) Polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (e.g.,)，

buffers and acids and bases (e.g. phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, tromethamine, triethanolamine),

isotonic agents (e.g. glucose, sodium chloride),

an adsorbent (e.g. highly dispersible silica),

viscosity-increasing agents, gel-forming agents, thickeners and/or binders (e.g. polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, starch, carbomer, polyacrylic acid (e.g.,) Alginate, gelatin),

disintegrants (e.g., modified starch, sodium carboxymethyl cellulose, sodium starch glycolate (e.g.,) Crospovidone, croscarmellose sodium (e.g.,))，

flow regulators, lubricants, glidants and mold release agents (e.g. magnesium stearate, stearic acid, talc, highly dispersible silicon dioxide (e.g. magnesium stearate, stearic acid, talc)))，

Coating materials (e.g. sugar, shellac) and film formers of films or diffusion films which dissolve rapidly or in a modified manner (e.g. polyvinylpyrrolidone)) Polyvinyl alcohol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, polyacrylate, polymethacrylate (e.g. hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate))，

Capsule materials (e.g. gelatin, hydroxypropylmethylcellulose),

synthetic polymers (e.g. polylactide, polyglycolide, polyacrylate, polymethacrylate (e.g. poly (lactide-co-glycolide))) Polyvinylpyrrolidone (e.g. polyvinylpyrrolidone)) Polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, polyethylene glycol, and copolymers and block copolymers thereof),

plasticizers (e.g.polyethylene glycol, propylene glycol, glycerol, triacetin, triacetyl citrate, dibutyl phthalate),

a penetration enhancer which is a mixture of at least one of,

stabilizers (e.g.antioxidants, such as ascorbic acid, ascorbyl palmitate, sodium ascorbate, butyl hydroxyanisole, butyl hydroxytoluene, propyl gallate),

preservatives (e.g. parabens, sorbic acid, thimerosal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate),

colorants (e.g. inorganic pigments, such as iron oxide, titanium dioxide),

flavours, sweeteners, taste and/or odour masking agents.

The invention also relates to a medicament comprising at least one compound of the invention, conveniently together with one or more inert, non-toxic, pharmaceutically suitable adjuvants, and the use of said medicament for the above-mentioned purposes.

Dosage and treatment regimen

The dosage and treatment regimen may and must vary depending on the type of cancer and the goal of the treatment.

The daily dose is generally between 20mg and 850mg and may be divided into a plurality of identical or different dosage units, preferably 2 dosage units which may be taken simultaneously or according to a certain schedule.

In particular, the daily dose is between 30mg and 500mg and can be divided into a plurality of identical or different dosage units, preferably 2 dosage units which can be taken simultaneously or according to a certain schedule.

The preferred daily dose is between 20mg and 400mg and may be divided into a plurality of identical or different dosage units, preferably 2 dosage units which may be taken simultaneously or according to a certain schedule.

More particularly, the daily dose is between 40mg and 300mg and can be divided into a plurality of identical or different dosage units, preferably 2 dosage units which can be taken simultaneously or according to a certain schedule.

More preferably the daily dose is between 20mg and 200mg and may be divided into a plurality of identical or different dosage units, preferably 2 dosage units which may be taken simultaneously or according to a certain schedule.

Even more preferred daily doses are between 50mg and 180mg and may be divided into a plurality of identical or different dosage units, preferably 2 dosage units which may be taken simultaneously or according to a certain schedule.

This applies both to monotherapy and to combination therapy with other anti-hyperproliferative, cytostatic or cytotoxic substances, which may require reduced doses.

The treatment may be performed in a periodically repeating cycle. The treatment cycle may have a varying duration, such as 21 days or 28 days, whereby administration is continuous or intermittent. The preferred cycle length is 28 days, whereby administration is continuous or intermittent.

A continuous schedule includes daily administration, e.g., 21 daily doses taken over a 21 day period, or 28 daily doses taken over a 28 day period. A preferred continuous schedule is to administer 28 daily doses over a 28 day period.

The intermittent schedule includes a treatment period followed by a non-treatment period, for example in a 21 day cycle or a 28 day cycle. The preferred cycle duration of the intermittent schedule is 28 days.

The treatment period may be repeated more than once in a given treatment cycle.

The treatment period may be, for example, 1 to 21 days, more preferably 3 to 14 days.

An even more preferred intermittent schedule includes 3 days of treatment followed by 4 days of no treatment in such a manner that it is repeated weekly to complete a 28 day treatment cycle.

Treatment is successful when there is at least stabilization of the disease and the extent of adverse events is readily treatable but at least acceptable. Thus, the number of treatment cycles applied may vary from patient to patient depending on the response and tolerability of the treatment.

Treatment is successful when there is at least stabilization of the disease and the extent of adverse events is readily treatable but at least acceptable.

Compound a may be used alone or (if desired) in combination with one or more other pharmacologically active substances, provided that the composition does not cause undesirable and unacceptable adverse effects. The present invention therefore also provides medicaments comprising a compound a according to the invention and one or more further active ingredients, in particular for the treatment and/or prevention of the abovementioned diseases.

For example, compound a may be used in combination with known anti-hyperproliferative, cytostatic, or cytotoxic agents for the treatment of cancer. It is particularly proposed to combine the compounds a of the invention with other substances for cancer therapy, or with radiotherapy.

Examples of suitable active ingredients for combined purposes include:

albumin-binding paclitaxel (abraxane), femitamide (afinitor), aldesleukin (aldesleukin), alendronic acid (alendronic acid), alpha ketone (alfaferone), alitretinoin (aldentinoid), allopurinol (allopurinol), sodium allopurinol (alprimerm), alloxazine (aloxi), altretamine (altramine), aminoglutethimide (aminoglutethimide), amifostine (amifostine), amrubicin (amrubicin), amsacrine (amsacrine), anastrozole (anastrozole), dolasemet (anzemet), alfa bepotastin (aranesp), parthenolide derivative (argatropine), arsenical trioxide (arsonidine), amesine (azacytosine), 5-azacytosine (5-azacytosine), betamethamine (azabetulin), Betamethasone (BCG), betadine sulfate (bledine), betadine, Betamethasone (BCG), betadine (bledine, betadine sulfate, betadine (bledine), betadine sulfate (BCG, betadine), betadine (sodium brome, amethodine), betadine (acartine, amethodine), betamethamine (sodium benzoate, betamethamine (sodium benzoate), betamethamine, betadine, betamethamine (sodium benzoate, betadine, sodium benzoate, and a, Bortezomib (bortezomib), busulfan (busufan), calcitonin (calcitonin), camphos (campath), capecitabine (capecitabine), carboplatin (carboplatin), casodex (casodex), cefesone (cemoleukin), daunorubicin (cerubidine), chlorambucil (chlamucil), cisplatin (cissplatin), cladribine (cladribine), clodronic acid (clodronic acid), cyclophosphamide (cyclophophamide), arabinoside (cyclabine), dacarbazine (dacarbazine), dactinomycin (dactinomycin), daunorubicin (daunorubicin), dexamethasone (decadronide), dexamethasone (dexrazoxane), estradiol valerate (estradiol), interleukin (diethylxanthosine), diethylstilbenine (diethylstilbenine), diethylstilbenine (doxorubine), dexrazine (doxorubin), doxorubin (doxorubin), diethylstilbenine (doxorubin), doxorubin (doxorubin), doxorubin, DW-166HC, leuprolide acetate (eligard), labyrine (elitek), epirubicin hydrochloride (ellence), aprepitant (emide), epirubicin (epirubicin), alphabetin (epoetin alfa), erythropoietin (epigenin), eptaplatin (eptaplatin), levamisole hydrochloride (ergamosol), estradiol (estrace), estradiol (estradiol), estramustine sodium phosphate (estramustine sodium phosphate), ethionamide (ethionylsadiol), amifostine (ethyol), oxyphosphate (ethidic acid), pyrithion (ethiodopter), etoposide (etoposide), fadrozole (fazozole), monophosphoryl (fareston), filgrastim (gradstim), finate (finasteride), nonfluorobine (fenamidofludine), fluxuridine (5-fluorouridine (5-fluorouracil (fluorouracil-5-fluorouracil (epirubicin), epirubicin (epirubicin, fadroxyuridine (e), norflurocidine), norfluridone (ethimide, norfluridone, norflur, Fluoromethyltestosterone (fluoxymatrine), flutamide (flutamide), formestane (formutane), fosetabine (fotemustine), fulvestrant (fulvestrant), gamma globulin (gamma), gemcitabine (gemcitabine), gemtuzumab (gemtuzumab), gleevec (gleevec), carmustine (gliadel), goserelin (goserelin), granisetron hydrochloride (granisetron hydrochloride), histrelin (histrelin), melatrelin (hycamtin), hydrocortisone (hydrocortisone), erythro-hydroxynonyladenine (erythro-hydroxynonylnylenenine), hydroxyurea (hydroxyurene), temebitumomab (hyalubulon), interferon alpha-interferon alpha (interferon alpha-1), interferon alpha-interferon alpha (interferon alpha-352), interferon alpha-352 (interferon alpha-1), interferon alpha-352 (interferon alpha-3535), interferon alpha-interferon alpha (interferon alpha-352), alpha interferon alpha-interferon alpha (interferon alpha-1), alpha interferon alpha-interferon alpha (interferon alpha-interferon, Interferon beta (interferon beta), interferon gamma-la (interferon gamma 1 alpha), interleukin-2 (interleukin 2), intron A (intron A), iressa (iressa), irinotecan (irinotecan), ketrey (kytiril), lapatinib (lapatinib), lentinan sulfate (lentinan sulfotate), letrozole (letrozole), leucovorin (leucovorin), leuprolide (leuprolide), leuprolide acetate (leuprolide acetate), levotetramisole (levamisole), levofolinic acid calcium salt (levofolinic acid), levothyroxine sodium (levothyroxine), levothyroxine (levothyroxine), megestrol (lostatin), lonidamine (lonidamine), cannabinoidamine (cannabinoidamine), cannabinol (megestrol acetate), megestrol (megestrol acetate), levothyroxine (levothyroxine), megestrol (megestrol acetate), megestrol (megestrol acetate), megestrol (megestrol acetate (megestrol), megestrol (megestrol acetate (megestrol), megestrol acetate (megestrol acetate), megestrol (megestrol acetate), megestrol acetate (megestrol), megestrol (, Mesna (mesna), methotrexate (methotrexate), metvix, miltefosine (miltefosine), milbemycin (minocycline), mitomycin C (mitomycin C), mitotane (mitotane), mitoxantrone (mitoxantrone), trostan (modal), daunomycin (myocet), nedaplatin (nedaplatin), filgrastim (neurasta), recombinant human interleukin 11 (neugega), eupatatin (neupogen), nilutamide (nilutamide), tamovadex (nolvadex), NSC-631570, OCT-43, octreotide (octreotide), ondansetron hydrochloride (ondansetron hydrochloride), orapiraperd (oxaliplatin), oxaliplatin (oxyplatin), taxol (prednisolone), prednisolone (prednisolone), predrypsin (prednisolone), prednisolone (sodium phosphate), prednisolone (prednisolone), prednisolone (prednisone hydrochloride), prednisone hydrochloride (prednisone hydrochloride), prednisolone (prednisone hydrochloride), prednisolone (prednisone hydrochloride (prednisolone), prednisolone (prednisone hydrochloride (prednisolone ), prednisone hydrochloride (prednisolone, prednisone hydrochloride), prednisolone, prednisone hydrochloride, predniso, Prednisone (prednisone), pemetrexed (premarin), procarbazine (procarbazine), purocorrin (procritit), raltitrexed (raltitrexed), RDEA119, ribi (rebif), rhenium-186etidronate (rhenium-186 ethidronate), rituximab (rituximab), dystrength-a (roferon-a), romopeptide (romide), pilocarpine (salagen), octreotide (sandostatin), sargramostim (sargramostim), semustine (semustine), sizopyrane (sizofian), sobutyloxane (sobuzoxazone), methylprednisolone (solumedronate), streptozotocin (strezozocin), strontium chloride-89, levothyroxine sodium (synthrothidine), ketotifen (ketotifen), sultamicin (suloctreotide), testoterone (triptolide), triptoterone (triptolide), triptoresin (triptolide), triptoresinolide (triptolide), triptolide (triptoresinolide (triptolide), temocine (triptostrobin (triptolide), temchloride-89), levothyroxine (triptolide), thyroxine (synthetic sodium (triptolide), triptostrobin (triptolide, Thioguanine (thioguanine), thiotepa (thiotepa), thyrotropin (thyrotropin), tiludronic acid (tiludronic acid), topotecan (topotecan), toremifene (toremifene), tositumomab (tositumomab), trastuzumab (trastuzumab), troosulfan (treosulfan), tretinoin (tretinoin), methotrexate (trexall), trimethamamelamine (trimetalmelamine), trimetrexate (trimetrexate), triptorelin acetate (triptorelin acetate), triptorelin pamoate (triptorelin paminoacetate), eugenine (eugenol), uridine (uridine), valrubicin (vinblastin), vinblastine (vinblastine), vincristine (vinblastine), vinorelbine (viniferine), vinorelbine (vincristine), vinorelbine (viniferine), viniferine (vincristine (vinblastine), vinblastine (vincristine), viniferine (vincristine (viniferine); ABI-007, aclobifene (acolbifene), interferon-1 b type C (actimum), affinitak, aminopterin (aminopterin), azoxifene (arzoxifene), ascorisil, atamestane (atamestane), atrasentan (atrasentan), BAY 43-9006 (sorafenib), avastin (avastin), CCI-779, CDC-501, celecoxib (celebrex), cetuximab (cetuximab), clinatrox (crisnatol), cyproterone acetate (cyproterone acetate), decitabine (decitabine), DN-101, adriamycin-MTC (doxorxobicin), dSLIM, doxylamine (dusteramide), ecotarein, avifenadine (vinclofenamide), histamine (irinotecan), histamine (adronate), histamine A-D-, intron-PEG (intron-PEG), ixabepilone (ixabepilone), keyhole limpet hemocyanin (keyhole limpet hemocyanin), L-651582, lanreotide (lanreotide), lasofoxifene (lasofoxifene), libra, lonafarnib (lonafarnib), miropoxifene (miproxifen), minodronate (minodronate), MS-209, liposomal MTP-PE (lipomamol MTP-PE), MX-6, nafarelin (nafarelin), nemorubicin (nemorubicin), neovastat (neovastatat), nolatrexed (nolatrexed), orlimersen (ometrimemersen), onotcs, osidase, paclitaxel polyglutamate (paclitaxel), polyglamide phosphonate (disodium), clavulanate (21-13), clavulanate (oxypyramide), oxypyrazine-2), oxyplatin (loxapine), oxyplatin-2, loxapine (loxapine), doxylamine (naproxobin (naproxene), loxacin-2), loxacin-PE (loxacin), loxacin-13, loxacin (loxacin), loxacin (loxacin), loxacin (loxacin-2, loxacin), loxacin, T-138067, Tarceva (tarceva), taxoprexin, thymosin alpha (thymosin alpha 1), thiazolecarboxidine (tiazofurin), tipifarnib (tipifarnib), tirapazamine (tirapazamine), TLK-286, toremifene, trans MID-lo7R (transMID-107R), valspodar, vapreotide (vapreotide), vatalanib (vatalanib), verteporfin (verteporfin), vinflunine (vinflunine), Z-100, zoledronic acid (zoledronic acid), and combinations thereof.

In a preferred embodiment, the compounds a of the invention can be combined with the following active ingredients:

131I-chTNT, abarelix (abarelix), abiraterone (abiraterone), aclarubicin (aclarubicin), aldesleukin, alemtuzumab (alemtuzumab), alitretinoin (altretamine), hexamethamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, fevernolide derivatives, arsenic trioxide, asparaginase (asparaginase), azacitidine (azacitidine), basiliximab (basiliximab), BAY 80-6946, belotecan (belotecan), bendamustine (bendamustine), bevacizumab (bevacizumab), bisaminol (bicalutamide), bisanate (biseartoxine), bleomycin, bortezomib, buserelin (buserelin), ampelin, cabazitaxel (cabazitaxel), cabazitaxel (calcium carbonate), cabazitaxel (calcium subcatex), betacellamustine (bevacizine (bevacizumab), betacellamustine), betacelluacin (bevacizine), bevacizine (bevacizumab), bevacizine (bevacizine), bevacizine (e), tacalcine (e), tacalci, Cetuximab, chlorambucil, chlormadinone, chlorambucil (chlorempene), cisplatin, cladribine, clodronic acid, clofarabine (clofarabine), crisantapase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, erythropoietin a (Darbepoetin alfa), dasatinib (dasatinib), daunomycin (daunorubicin), decitabine, degarelix (degarelix), dinium, denosumab (denosumab), deslorelin, dibromospiro-ammonium chloride (dibromopiridium chloride), docetaxel, deoxyuridine, adriamycin + estrone, eculizumab (edelomab), etimiumnium (aceticamide), lutepotate (luteotropium), epitrogliptin (epitrostatin), epibatidine (epibatidine), epirubicin (epirubicin), etidolomitinib (epitrostatin), epirubiginine (epitrostatin), etidolastine (epitrocoid), etidine (epirubicin), ritin (epitroglibenomycine, rituximab (epitrogliptin), rituximab (epirubicin), rituximab (epitroglibenomyl), ritin (epitroglibenomyl), clovisfate), clovisfatin (epitroglibenomyl (e), clovisfatin (clovisfate), clovisfatin (clo, Estradiol, estramustine (estramustine), etoposide, everolimus (everolimus), exemestane (exemestane), fadrozole (fadrozole), filgrastim, fludarabine, fluorouracil (flurouracil), flutamide, formestane, fotemustine, fulvestrant, gallium nitrate (gallimum nitrate), ganirelix (ganirelix), iressa (gefitinib), gemcitabine, gemtuzumab, daptomycin (glutoxim), goserelin, histamine dihydrochloride, histrelin, hydroxyurea (hydroxyurea), I-125 seed source, ibandronic acid, temetiracetam isometrimazumab, idarubicin, ifosfamide, imatinib (imatinib), imiqimod (imiduroid), improvasultin (irsulosin), interferon beta, interferon (interferon alpha-beta-interferon, galantamine (olamide), thalidomide, edermabolastine, vallisib, vallisuride (valnemadelomib), valnemadelomib, vallisib, valnemulin, vallisib, valnemadelomib, vallisib, valnemadelomib, valnemademab (valnemade, Lentinan (lentinan), letrozole, leuprolide (leuprorelin), levamisole, lisuride (lisuride), lobaplatin (lobaplatin), lomustine, lonidamine, mazoprocol (masoprocol), medroxyprogesterone (medroxyprogesterone), megestrol (megestrol), melphalan, meiandrane (mepitiostane), mercaptopurine (mercaptoprine), methotrexate, methoxsalen (methoxsalen), methyl aminolevulinic acid (methyinolevulinate), methyltestosterone (methyltestosterone), mivaquotide (mifamurtide), miltefosine, miriplatin (miriplatin), dibromomannitol (mitobenzoguanyl), mitoguazone (mitomycin), mitoxantrone (mitoxantrone), mitoxantrone (omeprazole), mitoxantrone (oxsultrine), mitoxantrone (e), mitoxantrone (mitoxantrone), mitoxantrone (mito, Oxaliplatin, p53 gene therapy, paclitaxel, palifermin (palifermin), palladium-103 seed source, pamidronic acid (pamidronic acid), panitumumab (panitumumab), pazopanib (pazopanib), pemetrexed (pegapargase), PEG-epoetin beta (epoetin beta) (methoxy-PEG-epoetin beta), pefilgrastim (pegfilgrastim), peginterferon alpha-2 b (peginteferon alfa 2b), pemetrexed (pemetrexed), pentazole neol (pentazocine), pentostatin, pellomycin (pelomomycin), pefosfamide (perfosfamide), picibanil, pirarubicin (pirarubicin), plexafop (plicamycin), plicamycin, chitosan (poliglum), polyxadiol (palatinol), polyquaternium (palatinomycin), paclitaxel, polacrine (palatinose), pamidronate (palatinomycin), picrolipramipexole (prallete, doxorubin), polacrine (palatine, pamidronate, picrorine, picrolite (palatine, picloratadine, picrin, picloran, picloratadine, picloran, piclorane, picloratadine, piclorane, picloratadine, piclorane, picloran, raltitrexed, ramustine (ranimustine), razoxane (razoxane), rafacitinib (refametinib), regorafenib (regorafenib), risedronic acid (risedronic acid), rituximab (rituximab), romidepsin (romidepsin), romidepsin (romiplosmist), samustine, sipuleucel-T, cezopyran, sobuzosin, sodium glycinedium glicididazole (Sorafenib), sorafenib, streptozocin, sunitinib (sunitinib), talaporfin (talaporfin), tamibarotene (tamitotene), tamoxifen, tasosamine, tesiline, tegafur (tegafur), tegafur + momab (gimeracil) + octreotide (oteracil) +), teteotaxifolin (tetabolin), tiotropin (tetoropine (tiotropine), tetrexin (tiotropine), tetoroxin (tiotropine (tetoroxin), tetoroxin (tiotropine), tetoroxin (tetoroxin), tetoroxin (netorhodorine), tetoroxin (tetoroxin), tetoroxin (tet, Toremifene, tositumomab, trabectedin, trastuzumab, troosulfan, treosulfan, tretinoin, trilostane, triptorelin, trofosfamide, tryptophan, ubenimex, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vinvinblastine, vinflunine, vinorelbine, vorinostat, vorozolozole, yttrium-90glass microspheres (ytrium-90 glass microspheres), neocarzinostatin, setastin, zoledronic acid, zorubicin, zorubinitib, sultaine, disodium, trovatamicin, sultaine, tretinomycin, albuterol, efavirenzab (Abromazine), and combinations thereof.

Desirably, compound a can also be combined with biological therapeutic agents such as antibodies (e.g., avastin (avastin), rituximab (rituxan), erbitux (erbitux), herceptin (herceptin), cetuximab) and recombinant proteins.

Compound a may also achieve positive effects in combination with other therapeutic agents directed against angiogenesis (e.g., avastin, axitinib, regorafenib, lotulin, sorafenib or sunitinib). Due to its advantageous properties in terms of adverse effects, combinations with inhibitors of proteasomes and mTOR and inhibitors of anti-hormones and steroid metabolic enzymes are particularly useful.

In general, the combination of compound a with other cytostatic or cytotoxic agents can achieve the following objectives:

improved efficacy in slowing tumor growth, reducing tumor size or even eliminating tumors altogether, compared to treatment with the active ingredient alone;

chemotherapy may be used at lower doses than monotherapy;

a more tolerable, less adverse therapy than administration alone;

a broader spectrum of neoplastic diseases can be treated;

higher therapeutic response rates are obtained;

the patient survives longer than current standard therapy.

Furthermore, the compounds a of the present invention may also be used in combination with radiotherapy and/or surgery.

Examples

1. Preparation of Compound A

Compound a' was prepared according to the method described in example 2 of WO 2014/076091.

2. In vitro experiments

2.1. Method of producing a composite material

2.1.1 cell lines

Table 1: list of DLBLC cell lines studied.

Indications of tumors	Subtype of cell	Examples of cell lines	Translocation (TL) or amplification (ampli) situations
				DLBCL	ABCa	HBL1	MYC TL
DLBCL	ABC	OCI-LY-3	MYC ampl/BCL2 ampl
				DLBCL	ABC	TMD8	MYC TL
DLBCL	GCBb	DB	BCL2 TL
				DLBCL	GCB	SU-DHL-6	MYC TL
DLBCL	GCB	HT	-
				DLBCL	GCB	OCI-LY-19	MYC TL
DLBCL	GCB	SU-DHL-8	MYC TL/BCL2 TL
				DLBCL	GCB	SU-DHL-10	MYC TL/BCL2 TL
DLBCL	GCB	SU-DHL-4	MYC ampl/BCL2 TL
				DLBCL	GCB	SU-DHL-5	-

^a(ii) an activated B-cell type,^bgerminal center B cell type

2.1.2 cell proliferation assay

Proliferation of all (DLCBL) cell lines in the presence of different concentrations of compound a' or FR compound was assessed using the CellTiter Glo kit (Promega Corporation, Madison, WI) for 72 hours. All values presented are the average of triplicate experiments and IC50 was calculated according to the manufacturer's instructions using GraphPad Prism 5(GraphPad software, San Diego, CA) or MTS software.

The FR compound is example 4 of WO2012/160034 and has the structure of formula II:

2.2 in vitro results

Table 2 summarizes the results of proliferation assays performed using compound a' or FR compounds. Table 2: list of cell lines studied and results of proliferation assays using compound a' or FR compounds.

		Practice ofExample (b)	Compound A'	FR compounds
					Indications of tumors	Subtype of cell	Cell lines	IC50[nmol/l]	IC50[nmol/l]
DLBCL	ABC	HBL1	196	540
					DLBCL	ABC	OCI-LY-3	83	340
DLBCL	ABC	TMD8	100	n/a
					DLBCL	GCB	DB	88	570
DLBCL	GCB	SU-DHL-6	37	360
					DLBCL	GCB	HT	81	710
DLBCL	GCB	OCI-LY-19	39	480
					DLBCL	GCB	SU-DHL-8	93	610
DLBCL	GCB	SU-DHL-10	129	600
					DLBCL	GCB	SU-DHL-4	90	170
DLBCL	GCB	SU-DHL-5	105	n/a

These in vitro data indicate that compound a' effectively inhibits the proliferation of ABC (activated B cell type) and GCB (germinal center B cell type) subtypes of Diffuse Large B Cell Lymphoma (DLBCL). These data recommend that compound a' be used to treat DLBCL patients.

3. In vivo experiments in mice using OCL-LY-3 diffuse Large B-cell lymphoma (DLBCL) xenograft model

The objective of this experiment was to assess the in vivo efficacy and tolerability of compound a' in monotherapy in a DLBCL OCI-LY-3 tumor model implanted subcutaneously in SCID mice.

In vivo efficacy was determined in female SCID mice carrying a subcutaneous DLBCL OCI-LY-3 xenograft. Compound a' was evaluated at one dosage level in monotherapy. The antitumor activity and tolerance of the treated group were evaluated using the vehicle control group as a reference.

To this end, OCI-LY-3 cells (0.1ml of 4X10 in 100% Matrigel (Matrigel)⁶Individual cells) were injected subcutaneously into the right flank of female SCID mice (Charles River). Animals and tumor implants were monitored daily until the maximum number of implants showed clear signs of starting solid tumor growth. Randomly, the area of the growing tumor was initially determined. According to the study protocol, will have an area of 25-35mm²The animals of (3) were assigned to the experimental group. The date of randomization was designated as day 0 of the experiment. Animals received compound a' intravenously at a dose of 10mg/kg (formulated with 30% PEG 400/10% ethanol/60% water) once every 7 days (q7d), or vehicle control (once daily (qd), oral (po)) for 14 days.

In the compound a 'group, no lethal toxicity occurred and the maximum body weight loss was-6%, while in the vehicle group was-4%, indicating that compound a' was well tolerated at a dose of 10mg/kg once every 7 days, by intravenous injection (iv).

At the end of the experiment, the ratio of treatment to control (T/C) was calculated from the average tumor area and the average tumor weight in compound a' treated group and vehicle control group. The mean tumor weight and mean tumor area were statistically significantly different, respectively. The area T/C of Compound A 'was 0.29 and the weight T/C was 0.24, indicating moderate in vivo activity of Compound A' in this model.

4. In vivo experiments in mice using SU-DHL-10 Diffuse Large B Cell Lymphoma (DLBCL) xenograft model

The objective of this experiment was to assess the in vivo efficacy and tolerability of compound a' in monotherapy in a DLBCL SU-DHL-10 tumor model implanted subcutaneously in SCID mice.

In vivo efficacy was determined in female SCID mice carrying a subcutaneous DLBCL SU-DHL-10 xenograft. Compound a' was evaluated at one dosage level in monotherapy. The antitumor activity and tolerance of the treated group were evaluated using the vehicle control group as a reference.

For this purpose, SU-DHL-10 cells (0.2ml of 10X10 in 50% matrigel)⁶Individual cells) were injected subcutaneously into female SCID mice (Taconic M)&B A/S, Denmark). Animals and tumor implants were monitored daily until the maximum number of implants showed clear signs of starting solid tumor growth. Randomly, the area of the growing tumor was initially determined. According to the study protocol, will have an area of 25-35mm²The animals of (3) were assigned to the experimental group. The date of randomization was designated as day 0 of the experiment. Animals received compound a' intravenously at a dose of 15mg/kg (formulated with 30% PEG 400/10% ethanol/60% water) once every 7 days (q7d) or vehicle control (i.v. once every 7 days) for 16 days.

In compound a 'group, the maximum weight loss was-9% and the vehicle group was-4%, indicating that compound a' was moderately tolerated at a dose of 7mg/kg, once every 7 days, upon intravenous injection.

At the end of the experiment, the ratio of treatment to control (T/C) was calculated from the mean tumor area of compound a' treated group and vehicle control group. The mean tumor area was statistically significantly different. The area T/C of compound a 'was 0.02, indicating that the in vivo activity of compound a' in this model was very high, corresponding to complete remission.

4.5. Conclusion and conclusions

These data indicate that compound a' has significant and meaningful anti-tumor activity in diffuse large B-cell lymphoma (DLBCL) patients.

Claims (16)

1. 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine of the formula (I) or one of its physiologically acceptable salts or enantiomers,

use in the manufacture of a medicament for the treatment of cancer in a subject, wherein the medicament is prepared for the treatment of diffuse large B-cell lymphoma, in particular diffuse large B-cell lymphoma of the germinal center B-cell type.

2. Use of a compound of formula (I) according to claim 1, wherein the medicament prepared is for the treatment of diffuse large B-cell lymphoma the cells of which have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

3. Use of a compound of formula (I) according to claim 1 or 2, wherein the enantiomer (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine or one of its physiologically acceptable salts is used.

4. The compound 5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulfonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine (Compound A, formula (I)),

the compounds are useful for the treatment of diffuse large B-cell lymphoma, especially diffuse large B-cell lymphoma of the germinal center B-cell type.

5. The compound according to claim 4, for use in the treatment of diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

6. A compound according to claim 4 or 5, wherein the enantiomer (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine or one of its physiologically acceptable salts is used.

7. 4- (4-fluoro-2-methoxyphenyl) -N- {3- [ (S-methylsulfonimidoyl) methyl ] phenyl } -1,3, 5-triazin-2-amine of the formula I or one of its physiologically acceptable salts or enantiomers

For the treatment and/or prevention of diffuse large B-cell lymphoma, in particular of germinal center B-cell type.

8. Use of a compound of formula (I) according to claim 7 for the treatment and/or prevention of diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

9. Use of a compound of formula (I) according to claim 7 or 8, wherein the enantiomer (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine or one of its physiologically acceptable salts is used.

10. A pharmaceutical combination comprising 4- (4-fluoro-2-methoxyphenyl) -N- {3- [ (S-methylsulphonimidoyl) methyl ] phenyl } -1,3, 5-triazin-2-amine of the formula I as defined in claim 1 or one of its physiologically acceptable salts or enantiomers

And at least one or more other active ingredients for the treatment and/or prevention of diffuse large B-cell lymphoma, in particular diffuse large B-cell lymphoma of the germinal central B-cell type.

11. A pharmaceutical composition comprising 4- (4-fluoro-2-methoxyphenyl) -N- {3- [ (S-methylsulphonimidoyl) methyl ] phenyl } -1,3, 5-triazin-2-amine of the formula I as defined in claim 1 or one of its physiologically acceptable salts or enantiomers

And at least one inert, non-toxic, pharmaceutically suitable adjuvant for the treatment and/or prevention of diffuse large B-cell lymphoma, in particular of the germinal central B-cell type.

12. The drug conjugate or the pharmaceutical composition according to claim 10 or 11, for the treatment and/or prevention of diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL 2.

13. Pharmaceutical combination or pharmaceutical composition according to any one of claims 12 to 25, comprising the enantiomer (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine or one of its physiologically acceptable salts.

14. Method for the treatment and/or prophylaxis of diffuse large B-cell lymphomas, in particular of the germinal center B-cell type, using an effective amount of 4- (4-fluoro-2-methoxyphenyl) -N- {3- [ (S-methylsulphonimidoyl) methyl ] phenyl } -1,3, 5-triazin-2-amine of formula I or one of its physiologically acceptable salts or enantiomers

15. The method of treatment and/or prevention of claim 14, wherein diffuse large B-cell lymphoma whose cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or overexpression of MYC and/or BCL2 is treated.

16. A method of treatment according to claim 14 or 15, wherein the enantiomer (+) -5-fluoro-4- (4-fluoro-2-methoxyphenyl) -N- {4- [ (S-methylsulphonimidoyl) methyl ] pyridin-2-yl } pyridin-2-amine or one of its physiologically acceptable salts is used.